Sec Form 3 Filing - Jovan-Embiricos Morana @ Cullinan Management, Inc. - 2021-01-07

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Jovan-Embiricos Morana 2. Issuer Name and Ticker or Trading Symbol Cullinan Management, Inc. [ CGEM] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUITE 520 3. Date of Earliest Transaction (MM/DD/YY) 01/07/2021 (Street) CAMBRIDGE, MA02142 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 112,507 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 4.3 ( 1 ) 10/28/2030 Common Stock 35,529 ( 3 ) D Stock Option (Right to Buy) $ 4.3 ( 1 ) 10/28/2030 Common Stock 104,845 ( 3 ) D Series Seed Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 1,136,525 I See footnote ( 3 ) Series A Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 2,912,345 I See footnote ( 4 ) Series A Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 639,295 I See footnote ( 5 ) Series B Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 455,338 I See footnote ( 6 ) Series B Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 182,135 I See footnote ( 7 ) Series C Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 71,599 I See footnote ( 6 ) Series C Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 143,198 I See footnote ( 7 ) Series C Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 71,599 I See footnote ( 8 ) Series C Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 214,798 I See footnote ( 9 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Jovan-Embiricos Morana C/O CULLINAN MANAGEMENT, INC. ONE MAIN STREET, SUITE 520 CAMBRIDGE, MA02142 X X Globeways Holdings Ltd C/O LJ PARTNERSHIP, 8, RUE SAINT-LEGER GENEVA, V8CH-1205 X F2 Vision SCS C/O ATALUX 74 GRAND-RUE LUXEMBOURG, V8L-1660 X F2 Bioscience I 2017 Ltd C/O LJ PARTNERSHIP, 8, RUE SAINT-LEGER GENEVA, V8CH-1205 X F2 MG Ltd C/O LJ PARTNERSHIP, 8, RUE SAINT-LEGER GENEVA, V8CH-1205 X F2 - TPO Investments LLC C/O SINGER, MCKEON INC. 8 WEST 38TH STREET, SUITE 1001 NEW YORK, NY10018 X F2 Bio TD, LLC C/O SINGER, MCKEON INC. 8 WEST 38TH STREET, SUITE 1001 NEW YORK, NY10018 X F2 MC, LLC C/O SINGER, MCKEON INC. 8 WEST 38TH STREET, SUITE 1001 NEW YORK, NY10018 X Signatures /s/ Morana Jovan-Embiricos 01/07/2021 Signature of Reporting Person Date /s/ Morana Jovan-Embiricos for Globeways Holdings Limited 01/07/2021 Signature of Reporting Person Date /s/ Alain Renard and Christian Francois for F2 Vision SCS 01/07/2021 Signature of Reporting Person Date /s/ Rachel Higham and Ivan Bedford for F2 Bioscience I 2017 Limited 01/07/2021 Signature of Reporting Person Date /s/ Morana Jovan-Embiricos for F2-TPO Investments, LLC 01/07/2021 Signature of Reporting Person Date /s/ Rachel Higham and Ivan Bedford for F2 MG Limited 01/07/2021 Signature of Reporting Person Date /s/ Morana Jovan-Embiricos for F2 Bio TD, LLC 01/07/2021 Signature of Reporting Person Date /s/ Morana Jovan-Embiricos for F2 MC, LLC 01/07/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )25% of the shares vested on March 8, 2018, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. ( 2 )Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 1-for-7.0390 basis into the number of common stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date. ( 3 )These securities are owned directly by Globeways Holdings Limited ("Globeways"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. ( 4 )These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. ( 5 )These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. ( 6 )These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. ( 7 )These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. ( 8 )These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. ( 9 )These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks: Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.